Share on StockTwits

Questcor Pharmaceuticals (NASDAQ:QCOR) Insider Don M. Bailey sold 40,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $91.96, for a total transaction of $3,678,400.00. Following the completion of the sale, the insider now directly owns 140,437 shares of the company’s stock, valued at approximately $12,914,587. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

QCOR has been the subject of a number of recent research reports. Analysts at Oppenheimer downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, July 25th. They now have a $86.00 price target on the stock. Analysts at Mizuho downgraded shares of Questcor Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, May 19th. They now have a $92.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $84.50.

Questcor Pharmaceuticals (NASDAQ:QCOR) remained flat at $93.60 during trading on Friday. Questcor Pharmaceuticals has a one year low of $47.71 and a one year high of $97.80. The stock has a 50-day moving average of $92.90 and a 200-day moving average of $81.15. The company has a market cap of $5.587 billion and a price-to-earnings ratio of 16.41.

Questcor Pharmaceuticals (NASDAQ:QCOR) last announced its earnings results on Thursday, July 24th. The company reported $1.85 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.11. The company had revenue of $278.80 million for the quarter, compared to the consensus estimate of $261.02 million. During the same quarter in the previous year, the company posted $1.12 earnings per share. The company’s revenue for the quarter was up 38.5% on a year-over-year basis. Analysts expect that Questcor Pharmaceuticals will post $6.94 EPS for the current fiscal year.

Questcor Pharmaceuticals, Inc (NASDAQ:QCOR) is a biopharmaceutical company.

Receive News & Ratings for Questcor Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Questcor Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.